Benjamin Hickey - 07 Jan 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: EVP, Chief Commercial Officer
Signature: /s/ Vickie Reed, Attorney-inFact
Issuer symbol: N/A
Transactions as of: 07 Jan 2022
Net transactions value: -$266,984
Form type: 4
Filing time: 07 Jan 2022, 19:27:00 UTC
Previous filing: 05 Jan 2022
Next filing: 18 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Sale	$266,984	-1,964	-7.3%	$135.94	24,848	07 Jan 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020.
F2	The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $135.6428 to $135.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020.

The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $135.6428 to $135.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.